Deutsche Bank AG Acquires New Shares in Xencor, Inc. $XNCR

Key Points

• Deutsche Bank initiated a position in Xencor, purchasing 119,822 shares worth approximately $1.93 million, or about 0.16% of the biopharmaceutical company.
• Analyst sentiment remains mixed: five analysts rate Xencor a Buy, three a Hold and one a Sell. The consensus rating is Hold, with an average price target of $24.86.
• Xencor’s latest quarter exceeded expectations, reporting an adjusted loss of $0.29 per share versus an expected loss of $0.80 and revenue of $51.22 million, up 17.4% year over year.

Deutsche Bank AG bought a new stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 119,822 shares of the biopharmaceutical company's stock, valued at approximately $1,929,000. Deutsche Bank AG owned approximately 0.16% of Xencor at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of XNCR. Tower Research Capital LLC TRC grew its stake in shares of Xencor by 118.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company's stock valued at $44,000 after buying an additional 3,018 shares in the last quarter. E Fund Management Co. Ltd. acquired a new position in Xencor in the second quarter worth approximately $79,000. iSAM Funds UK Ltd bought a new position in Xencor during the second quarter valued at approximately $122,000. Prelude Capital Management LLC bought a new position in Xencor during the third quarter valued at approximately $139,000. Finally, Creative Planning lifted its stake in Xencor by 25.3% in the second quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company's stock valued at $143,000 after acquiring an additional 3,661 shares during the last quarter.

Analyst Ratings Changes

XNCR has been the subject of several recent research reports. Cantor Fitzgerald boosted their target price on shares of Xencor from $43.00 to $44.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Weiss Ratings restated a "sell (d-)" rating on shares of Xencor in a report on Wednesday, June 24th. Zacks Research raised shares of Xencor from a "strong sell" rating to a "hold" rating in a research note on Monday, July 6th. Royal Bank Of Canada upped their price objective on shares of Xencor from $19.00 to $20.00 and gave the stock an "outperform" rating in a report on Thursday, August 6th. Finally, Wall Street Zen raised shares of Xencor from a "strong sell" rating to a "hold" rating in a research report on Saturday, August 8th. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $24.86.

Xencor Stock Down 9.8%

NASDAQ:XNCR opened at $26.06 on Friday. Xencor, Inc. has a 12 month low of $7.83 and a 12 month high of $30.61. The firm has a market cap of $1.94 billion, a price-to-earnings ratio of -12.01 and a beta of 0.85. The company's 50 day moving average is $19.80 and its 200-day moving average is $14.77.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.51. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The business had revenue of $51.22 million during the quarter, compared to the consensus estimate of $18.89 million. During the same period in the prior year, the firm earned ($0.41) EPS. Xencor's quarterly revenue was up 17.4% compared to the same quarter last year. Research analysts predict that Xencor, Inc. will post -3 EPS for the current fiscal year.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor's research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.